Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Phreesia (New York City, NY) a commercial-stage provider of patient check-in systems, closed a $20M Series D financing. Participants include VantagePoint, Ascension Health Ventures, Polaris Venture Partners, HLM Venture Partners, Long River Ventures and BlueCross BlueShield Venture Partners.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

T2 Biosystems (Cambridge, MA) a development-stage molecular and immunodiagnostic company focused on a nanotechnology and miniaturized magnetic resonance designed to optimize sample prep, closed a $12M Series C financing. Participants include Physic Ventures, Arcus Ventures, RA Capital, Camros Capital, WS Investments, Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare.

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Apnex Medical (St. Paul, MN) a clinical-stage medical device company developing an implantable treatment for moderate-to-severe obstructive sleep apnea, closed a $14M Series B financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture […]

Fate Therapeutics (La Jolla, CA) a pre-clinical biopharma company focused on developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate tissue regeneration and blocking cancer growth, closed a $30M Series B financing. Participants include OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock. Note: 2009 Year-in-Review Trend Analysis […]

Adimab (Lebanon, NH) a commercial-stage yeast-based antibody discovery and optimization platform, closed a $8.2M Series D financing. Participants include Google Ventures, OrbiMed, Borealis Ventures,Polaris Venture Partners and SV Life Sciences. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

« Previous Page  Next Entries »

to top of page...